AzTrials
AzTrials

Parkinson DiseasePhase 1/2NouvNeu001-01NCT07102342

This Clinical Trial is Designed to Evaluate the Safety, Tolerability, Feasibility and Preliminary Efficacy of NouvNeu001 (Human Dopaminergic Progenitor Cells Injection) in Patients With Parkinson's Disease.

A Phase 1/2 study testing Human Dopaminergic Progenitor Cells in people with Parkinson Disease, run by iRegene Therapeutics Co., Ltd. at 1 site in United States.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

This is a phase 1/2 clinical study to evaluate the safety, tolerability, feasibility, and preliminary efficacy of NouvNeu001 in patients with advanced Parkinson's Disease. Read more about this study

Who is it for?
Ages 30 to 75 years
Conditions the study is for
Parkinson Disease
What is being tested?
Human Dopaminergic Progenitor Cells
Type of treatment
Injection or infusion
Could I receive a placebo?
No, everyone receives an active treatment
How many people
5 participants
Where
1 siteUnited States
Study dates
12 Jan 2026to Sep 2032
Phase
Phase 1/2
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 30 to 75 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Age
  • Male or female patient must be 30 to 75 years of age inclusive, at the time of signing the informed consent form (ICF).
  • Type of Patient and Disease Characteristics
  • Diagnosis of PD between past 4 to 20 years (meet MDS 2015 clinical diagnostic criteria for PD).
  • H-Y staging (Appendix III) for "OFF" episodes is 2.5-4.0.
  • MDS-UPDRS-III score > 35, and positive for the Acute levodopa challenge test (ALCT) (improvement > 30% for MDS UPDRS-III staging from OFF episodes to ON episodes) over two screening period visits. Baseline scores will be computed as the means of two screening period visits.
Show all 27Show fewer
  • No significant change in UPDRS-III scores between the two visits during the screening period.
  • Patients who take stable doing of dopamine drug for at least 4 weeks prior to receiving the study drug.
  • No significant change in dose and dosing schedule of the prescribed medicines for PD during the screening period.
  • Medically suitable for neurosurgery under general anesthesia.
  • Acceptable laboratory test values during screening and prior to transplantation (Day 0):
  • Absolute neutrophil count ≥ 2.0 × 109/L
  • White blood cell count ≥ 4.0 × 109/L
  • Platelet count ≥ 100 × 109/L
  • Aspartate aminotransferase (AST) and alanine transaminase (ALT) ≤ 2.5 x upper limit of normal (ULN)
  • Total bilirubin ≤ 1.5 x ULN
  • Serum creatinine ≤ 1.5 x ULN
  • eGFR ≥ 50 mL/min/1.73 m2
  • Agree to postpone any additional neurosurgical procedures, including DBS, until completion of the 12-month follow-up study (unless recommended by a neurologist).
  • Agree not to participate in any other therapeutic intervention study within 24 months after neurosurgery.
  • Able to participate in all study visits and evaluations, including brain/spine MRI, CT and PET scan.
  • Weight • Body mass index (BMI) within the range of 18~32 kg/m2 (inclusive) with a minimum body weight of 45 kg at screening.
  • Sex and Contraceptive/Barrier Requirements
  • Contraceptive use by men and women for 12 months after neurosurgery should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
  • Informed Consent
  • Able to understand the rationale of the clinical trial and sign the ICF. Other Inclusion Criteria
  • Agree not to receive COVID-19 vaccine within 14 days before neurosurgery, and not to receive any other vaccine within 30 days after neurosurgery

Who cannot join

  • Medical Conditions
  • Atypical Parkinsonism (Parkinsonism-Plus syndrome, secondary parkinsonism, familial parkinsonism) Prior/Concomitant Therapy
  • Patients who have had previous pallidotomy, DBS surgery, striatal or extrapyramidal surgery, brain stereotaxy, prior surgical or radiation therapy to the brain or spinal cord, or other brain surgery; as well as other surgical procedures that, in the investigator's judgment, could interfere with participation in this study.
  • Patients who have a previous head CT/MRI examination showing cerebral trauma, vascular malformation, hydrocephalus, brain tumor, etc., and patients who have brain imaging abnormalities in the striatum or other brain areas leading to a significantly increased risk for surgery.
  • Patients who have had previous cellular therapy.
  • Patients who have used glucocorticoids for an extended period (≥14 days) and at high doses (equivalent to prednisone ≥ 20 mg/day or other glucocorticoids at equivalent doses) within 3 months prior to signing the ICF. (excluding topical treatment)
Show all 52Show fewer
  • Patients who have used immunosuppressive drugs for an extended period (≥14 days) within 3 months prior to signing the ICF.
  • Patients who have used antipsychotics, such as antidepressants, antimanic drugs, etc. within 3 months prior to signing the ICF and are deemed by the investigator to potentially impact the study assessment.
  • Patients who have used botulinum toxin or other drugs for dystonia or muscle spasticity within 6 months prior to signing the ICF and are deemed by the investigator to potentially impact the study assessment.
  • Prior/Concurrent Clinical Study Experience
  • Patients who are participating in other clinical trials, or have been enrolled in other clinical studies within 3 months prior to the screening
  • Patients with poor compliance based on clinical evaluation of the investigator. Diagnostic Assessments
  • Patients with a history of dementia or a severe cognitive disorder; or those with obvious dementia or congnitive impairment detected during screening; MDS-UPDRS congnitive impairment score (section 1.1) > 3 point at screening; or patinets with poor compliance, inability to accurately keep diary, and/or inability to sign ICF due to dementia.
  • Severe depression as defined by HAMD ≥ 24 at screening.
  • Severe anxiety as defined by HAMA ≥ 29 at screening.
  • Patients with a history of psychiatric disorders that, in the investigator's opinion, make them unsuitable for participation; or patients with a history of suicidal ideation or suicide attempts within the past year or currently (including actual attempts, interrupted attempts, or failed attempts).
  • Patients with abnormal coagulation (prothrombin time ≥ 1.5 ULN, activated partial thromboplastin time ≥ 1.5 ULN), or abnormal INR at screening.
  • Patients cannot temporarily suspend anti-platelet agents or other anti-coagulant medications at least 5 days prior to investigational drug administration surgery.
  • Patients with active disseminated intravascular coagulation and significant hemorrhagic tendency within 3 months prior to signing the ICF.
  • Patients with current or history of following disease
  • severe heart failure (congestive heart failure of New York Heart Association Class II or above), unstable angina pectoris, and myocardial infarction
  • severe arrhythmia, including but not limited to second- or third-degree atrioventricular block, or prolonged QT interval.
  • Long QT Syndrome.
  • cardiovascular surgery (cardiac, vascular stent surgery, angioplasty).
  • stroke or transient ischemic attack within 3 months prior to signing the ICF, as determined by the investigator to be unsuitable to participate the study.
  • subarachnoid hemorrhage
  • primary mitochondrial disorder, multiple sclerosis, or other neurodegenerative diseases such as Alzheimer's disease
  • major vascular diseases (aortic aneurysm, aortic dissecting aneurysm, internal carotid artery stenosis), as determined by the investigator to be unsuitable to participate the study.
  • previous or current malignant tumors
  • immune disfunction, including autoimmune disease or immunocompromised state
  • traumatic brain injury with loss of consciousness and residue neurologic symptoms
  • active epilepsy or currently on anti-epileptic drugs
  • Hypertensive patients with poorly controlled blood pressure (defined as blood pressure above 160/100 mmHg despite antihypertensive drugs treatment) and patients with severe postural hypotension
  • Diabetic patients with poorly controlled blood glucose (glycosylated hemoglobin > 9.0%, or fasting plasma glucose (FPG) ≥ 11.1mmol/L)
  • Patients with clinically significant abnormalities in kidney or liver function at screening.
  • Patient with clinically significant abnormalities in immunological tests at screening
  • Patients with surgical contraindications (such as those with cochlear implant, cardiac pacemaker, cardiac defibrillator, stereotactic nucleus pallidotomy; Patients who have had unilateral or bilateral intraparenchymal implantation of cellular products, or other surgical procedures within 6 months before screening which, in the opinion of the investigator, have an impact on this trial; Patients with other neurosurgical contraindications)
  • Patients with other combined severe systemic diseases, such as pulmonary heart disease, moderate to severe asthma, severe chronic obstructive pulmonary disease (COPD) (FEV1% < 50%)
  • Patients with serious infections, requiring antibiotic treatment within 2 weeks prior to signing the ICF
  • Patients with any active infectious disease, including but not limited to positive for human immunodeficiency virus, SARS Covid-19 virus, syphilis antibody, quantitative HCV-RNA testing, quantitative HBV-DNA testing greater than normal range for test results, or untreated tuberculosis; any other active infection that, in the investigator's opinion, may affect the participant's ability to take part in the study or could impact study outcomes.
  • Other Exclusion Criteria
  • Patients with alcohol or drug addiction
  • Patients with contraindications or a history of allergy to any medicines used during the neurosurgical procedure.
  • Patients with contraindication or a history of allergy to any medicines used during the study, such as immunosuppressants, levodopa, etc, or any of their components; Patients who are allergic to similar drugs or other macrolides.
  • Female of childbearing potential who are not surgically sterilized/premenopausal/unwilling to use medically approved effective contraception during the study and lactating women; men who are not surgically sterilized/unwilling to use medically approved effective contraception during the study
  • Patients who have received electric shock therapy within 30 days prior to the investigational drug administration surgery
  • Patients who are participating in other clinical trials, or have been enrolled in other clinical studies within 3 months prior to the screening
  • Patients with poor compliance based on clinical evaluation of the investigator
  • Patients who are being treated with drugs such as neuroleptics, apomorphine, or levodopa/carbidopa infusion therapy
  • Patients with severe dyskinesia in both "ON" and "OFF" drug states
  • Patients who have received or will receive a live vaccine within 4 weeks prior to the study
  • Patients with significant medical conditions, or with other conditions that, in the opinion of the investigator, are unsuitable to participate in the study

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Meng Cai, Ph.D contact

0086-027-59337986

caimeng@iregene.com

Jing Zhao, PhD contact

zhaojing@iregene.com

United States1 site, 1 recruiting

  • Cornell University Weill Medical College

    New York, New York, 10065

    Recruiting

Other trials in United States

About this study

Official title: A Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Feasibility, and Preliminary Efficacy of NouvNeu001 in Patients With Advanced Parkinson's Disease.

This is a phase 1/2 clinical study to evaluate the safety, tolerability, feasibility, and preliminary efficacy of NouvNeu001 in patients with advanced Parkinson's Disease.

Read the detailed description

This is a multi-center, single arm, and open label trial. The NouvNeu001 will be transplanted into the bilateral putamen/striatum using stereotactic neurosurgery. Subjects will take immunosuppressants to prevent potential immune rejection for 24 to 36 weeks.

Being tested
Human Dopaminergic Progenitor Cells
Keywords
NouvNeu001, Human Dopaminergic Progenitor Cells Injection, phase 1 study, Dopaminergic Progenitor Cells
Medical subject headings
Parkinson Disease

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Human Dopaminergic Progenitor CellsBiological

    Also called NouvNeu001

    Single injection of Human Dopaminergic Progenitor Cells into the biliteral putamen/striatum regions of the brain

Study groups in NCT07102342
Study groupRoleWhat they receive
NouvNeu001ExperimentalSingle injection of Human Dopaminergic Progenitor Cells into the bilateral putamen/striatum regions of the brain.
Receives: Biological: Human Dopaminergic Progenitor Cells

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Safety and Tolerability

    Incidence and severity of adverse events (AEs) and serious adverse events (SAEs).

    Measured: 24 weeks and 48 weeks post-transplant

Secondary outcomes (2)

  1. The Motor Function and Non-motor Function

    Changes in MDS-UPDRS Part I-IV Score from baseline to 48 weeks and 96 weeks post-transplant. A higher score indicates more severe symptoms or worse health.

    Measured: 48 weeks and 96 weeks post-transplant

  2. Continued Safety and Tolerability

    Incidence and severity of AEs and SAEs within 96 weeks and 15 years post-transplant.

    Measured: 96 weeks and 15 years post-transplant

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted3 Aug 2025
  2. Study start12 Jan 2026
  3. Primary completionSep 2027 (estimated)
  4. Study completionSep 2032 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1/2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
5 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07102342
Sponsor's protocol ID
NouvNeu001-01
Acronym
NouvNeu001-01
Status last verified
Mar 2026
First submitted
28 Jul 2025
Last updated
11 May 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A Phase 1/2 study testing Human Dopaminergic Progenitor Cells in people with Parkinson Disease, run by iRegene Therapeutics Co., Ltd. at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 27 inclusion and 52 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 11 May 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this combined phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Meng Cai, Ph.D (0086-027-59337986, caimeng@iregene.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Safety and Tolerability (time frame: 24 weeks and 48 weeks post-transplant). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07102342.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 May 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in